Special drug-use survey of Tarlige (central neuropathic pain)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220132

Enrollment

400

Registered

2022-06-12

Start date

2022-07-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central neuropathic pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with central neuropathic pain not treated with Tarlige before (2) Patients who started administration of Tarlige during the contract period (contract period based on the contract with each medical site) (3) Patients who started administration of Tarlige during the registration period (4) Patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Occurrence of adverse drug reactions stratified by the causative diseases of neuropathic pain	—

Secondary

Measure	Time frame
Change in VAS (Visual Analogue Scale) of pain	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results